Table 5.

Change of ALBI score in proof-of-concept study

	Baseline	1 month	2 months	3 months	EOT
Lenvatinib	–2.61	–2.45	–2.40*	–2.49**	–2.61
TACE	–2.66	–2.25#	–2.24#,*	–2.15#,**	–2.09#

Cited and modified from Kudo et al. [34]. ALBI score, albumin-bilirubin score; EOT, end of treatment; TACE, transcatheter arterial chemoembolization.

^*p < 0.05, lenvatinib vs. TACE;

^**p < 0.01, lenvatinib vs. TACE;

^#p < 0.01, vs. TACE at baseline.